MCM
BMRN icon

Moore Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Moore Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-325,000
Closed -$19.3M – 662
2025
Q4 		$19.3M Buy
+325,000
New +$17.7M 0.28% 95
2024
Q3 		– Sell
-250,000
Closed -$20.6M – 470
2024
Q2 		$20.6M Sell
250,000
-10,000
-4% -$833K 0.36% 86
2024
Q1 		$22.7M Buy
260,000
+50,000
+24% +$4.48M 0.36% 66
2023
Q4 		$20.2M Buy
210,000
+14,800
+8% +$1.31M 0.35% 53
2023
Q3 		$17.3M Buy
195,200
+35,200
+22% +$3.13M 0.32% 60
2023
Q2 		$13.9M Buy
160,000
+130,000
+433% +$12.2M 0.24% 78
2023
Q1 		$2.92M Sell
30,000
-100,000
-77% -$10.4M 0.06% 210
2022
Q4 		$13.5M Buy
130,000
+76,012
+141% +$7.14M 0.32% 49
2022
Q3 		$4.58M Sell
53,988
-20,576
-28% -$1.83M 0.11% 209
2022
Q2 		$6.18M Buy
74,564
+17,207
+30% +$1.37M 0.16% 139
2022
Q1 		$4.42M Sell
57,357
-114,714
-67% -$9.6M 0.11% 224
2021
Q4 		$15.2M Buy
+172,071
New +$14.2M 0.3% 63
2016
Q1 		– Sell
-122,000
Closed -$12.8M – 249
2015
Q4 		$12.8M Buy
+122,000
New +$12.7M 0.4% 72
2015
Q2 		– Sell
-27,500
Closed -$3.43M – 426
2015
Q1 		$3.43M Sell
27,500
-28,600
-51% -$3.03M 0.08% 215
2014
Q4 		$5.07M Buy
+56,100
New +$4.67M 0.16% 137
2013
Q4 		– Sell
-62,500
Closed -$4.51M – 375
2013
Q3 		$4.51M Buy
+62,500
New +$4.15M 0.1% 167

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Moore Capital Management's BMRN Position: Q1 2026 in Review

Moore Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 325,000 shares — an estimated $19.3M sold.

Moore Capital Management first reported a position in BMRN in Q3 2013 and held it in 16 quarters. The position peaked at $22.7M in Q1 2024. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Moore Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Moore Capital Management sold 325,000 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $19.3M.
  • Moore Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 16 quarters.
  • Moore Capital Management's BioMarin Pharmaceuticals position peaked at $22.7M in Q1 2024.
  • 559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.